MEA Smart Inhalers Market

MEA Smart Inhalers Market Size (2023 to 2028)

The size of the Middle East and Africa smart inhalers market was worth USD 7.47 million in 2023 and is estimated to grow at a CAGR of 67.1% to reach USD 97.31 million by 2028.

The growing prevalence of chronic respiratory disorders across the MEA region propels the MEA smart inhalers market growth. In the Middles East region, nearly 60 million people suffer from respiratory illness, the fourth leading cause of death worldwide. Smart inhalers are used by a patient suffering from respiratory disorders to access their data remotely by the healthcare providers during the patient’s active use of the device. This helps provide better treatment and inhalation technicians to the patient for immediate treatment of the disorder.

The increasing geriatric population and increasing environmental pollution are the other factors that help the growth of the market. With increasing age, most people suffer from respiratory disorders due to weak respiratory systems and body strength. The senior population also uses these smart inhalers to monitor insulin intake in patients with diabetes. Additionally, increasing air pollution due to increasing automobile usage in the region also leads to demand for smart inhalers from the population. Furthermore, air pollution can worsen asthma symptoms among the population. All these factors help in the development of smart inhalers in the region.

Increasing focus on developing advanced inhalers is boosting the regional market growth. Using advanced technologies such as artificial intelligence in the software to improve patient safety and quality of life and manufacturing personalized smart inhalers for the respective people or groups also help with the market's demand. Increasing investment by pharmaceutical companies, research and development, and clinical centers are the other factors for market growth.

The high cost of smart inhalers is the major restrain of the market growth. In addition, lack of awareness of the inhalers, less availability of the products, and long approval time for the novel inhalers are the other factors hamper the market growth.

This research report on the MEA smart inhalers market has been segmented and sub-segmented into the following categories:

By Product Type: 

• Nebulizers
• Inhalers

By Disorder: 

• Chronic Obstructive Pulmonary Disease
• Asthma
• Others

By End-user: 

• Patients
• R&D
• Others

By Country: 

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

The Middle East and Africa held a moderate share of the worldwide market in 2023 and are expected to grow steadily during the forecast period owing to the growing number of approvals of advanced medical devices. The government has taken several measures to approve smart inhalers for respiratory devices in this region. In addition, increasing awareness programs regarding smart inhalers among the population to increase the demand also helps the market growth.

The Egyptian market is expected to showcase a healthy CAGR during the forecast period owing to the increasing prevalence of asthma cases. In Egypt, nearly 7 percent of the population suffers from asthma. The increasing death rate among asthma and respiratory disorder patients demands smart inhalers to lead a quality life. Most smokers have asthma in the region. Asthma illness results in chest tightness, expiratory wheezing, and breathing problem in the population. Additionally, increasing kerosene stoves, portable stoves, and biomass fuel for cooking in rural areas also leads to respiratory problems.

The smart inhalers market in UAE and Saudi Arabia are predicted to hold a substantial share of the MEA during the forecast period owing to the increasing investments by the local market players for manufacturing smart inhalers for all age groups. Nearly 14 percent of the UAE population is impacted by asthma. In addition, children between the of 6-12 also suffer from moderate to severe asthma, which requires appropriate smart inhalers for treatment. In recent years, Activ8rlives PUFFClicker, a smart inhaler for asthma disease, launched an application to track the drug quantity inhaled at a time, count dosage, etc.

KEY MARKET PLAYERS:

Companies such as Vectura Group plc, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Boehringer Ingelheim GmbH, AstraZeneca plc, Adherium Limited, Cohero Health, LLC, Propeller Health, GlaxoSmithKline plc, and OPKO Health, Inc. are playing a significant role in the MEA smart inhalers market.